Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | HMGCR | P04035 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | LPL | P06858 | 2/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.31 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29704024 | 1.00 | TAAR1 (0.38) | TAAR1EGFRUCHL1CSF1RHMGCR | |
| SCHEMBL14659310 | 0.85 | EGFR (0.36) | EGFR | |
| SCHEMBL16637155 | 0.84 | LPL (0.36) | P2RX7ROCK1LPLLIPGCXCR2 | |
| SCHEMBL18819293 | 0.83 | LPL (0.34) | EGFRLPLLIPG | |
| SCHEMBL14406854 | 0.83 | EGFR (0.39) | EGFRCSF1RLPLLIPGLMNA | |
| SCHEMBL18805560 | 0.80 | JAK2 (0.36) | UCHL1ROCK1LPLLIPGCXCR2 | |
| SCHEMBL17258894 | 0.79 | DGAT1 (0.40) | NPC1MAPK1 | |
| SCHEMBL29652912 | 0.79 | DGAT1 (0.40) | NPC1MAPK1 | |
| SCHEMBL28598599 | 0.79 | EGFR (0.44) | TAAR1EGFRCSF1RLPLLIPG | |
| SCHEMBL29470635 | 0.79 | ROCK1 (0.35) | ROCK1LPLLIPGCXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110573508-B | Fused imidazo-piperidine JAK inhibitor compounds | 施万生物制药研发IP有限责任公司 | 2022-07-05 | — | — | CN | disclosed |
| US-20220008428-A1 | FUSED IMIDAZO-PIPERIDINE JAK INHIBITOR COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-01-13 | — | — | US | disclosed |
| US-20220008428-A1 | FUSED IMIDAZO-PIPERIDINE JAK INHIBITOR COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-01-13 | — | — | US | disclosed |
| EP-3601283-B1 | FUSED IMIDAZO-PIPERIDINE JAK INHIBITOR COMPOUND | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2021-12-29 | — | — | EP | disclosed |
| US-11160810-B2 | Fused imidazo-piperidine JAK inhibitor compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-11-02 | — | — | US | disclosed |
| US-11160810-B2 | Fused imidazo-piperidine JAK inhibitor compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200046719-A1 | FUSED IMIDAZO-PIPERIDINE JAK INHIBITOR COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-02-13 | — | — | US | disclosed |
| US-20200046719-A1 | FUSED IMIDAZO-PIPERIDINE JAK INHIBITOR COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-02-13 | — | — | US | disclosed |
| EP-3601283-A1 | FUSED IMIDAZO-PIPERIDINE JAK INHIBITOR COMPOUND | Theravance Biopharma R&D IP, LLC (US) | 2020-02-05 | — | — | EP | disclosed |
| CN-110573508-A | Fused imidazo-piperidine JAK inhibitor compounds | 施万生物制药研发IP有限责任公司 | 2019-12-13 | — | — | CN | disclosed |
| US-10493077-B2 | Fused imidazo-piperidine JAK inhibitor compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-12-03 | — | — | US | disclosed |
| WO-2018204238-A1 | FUSED IMIDAZO-PIPERIDINE JAK INHIBITOR COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-11-08 | — | — | WO | disclosed |
| US-20180311255-A1 | FUSED IMIDAZO-PIPERIDINE JAK INHIBITOR COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-11-01 | — | — | US | disclosed |
| EP-2736907-B1 | INDAZOLES | PFIZER LTD (GB) | 2015-10-07 | — | — | EP | disclosed |
| US-8895544-B2 | Indazoles | PFIZER LIMITED (GB) | 2014-11-25 | — | — | US | disclosed |
| EP-2736907-A1 | INDAZOLES | Pfizer Limited (GB) | 2014-06-04 | — | — | EP | disclosed |
| US-20140024634-A1 | INDAZOLES | PFIZER LIMITED (GB) | 2014-01-23 | — | — | US | disclosed |
| US-8575336-B2 | Indazoles | PFIZER LIMITED (GB) | 2013-11-05 | — | — | US | disclosed |
| US-20130029968-A1 | INDAZOLES | PFIZER LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| WO-2013014567-A1 | INDAZOLES | PFIZER LIMITED (GB) | 2013-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029968-A1 | INDAZOLES | CYP11B2, CYP11B1, IL33 | TAAR1 4024/4885EGFR 3462/4885UCHL1 3362/4885 |
| US-20220008428-A1 | FUSED IMIDAZO-PIPERIDINE JAK INHIBITOR COMPOUND | JAK1, JAK2, JAK3 | TAAR1 2608/4885EGFR 464/4885UCHL1 4457/4885 |
| US-10493077-B2 | Fused imidazo-piperidine JAK inhibitor compound | JAK1, JAK2, JAK3 | TAAR1 2608/4885EGFR 464/4885UCHL1 4457/4885 |
| US-11160810-B2 | Fused imidazo-piperidine JAK inhibitor compound | JAK1, JAK2, JAK3 | TAAR1 2608/4885EGFR 464/4885UCHL1 4457/4885 |
| US-20180311255-A1 | FUSED IMIDAZO-PIPERIDINE JAK INHIBITOR COMPOUND | JAK1, JAK2, JAK3 | TAAR1 2608/4885EGFR 464/4885UCHL1 4457/4885 |
| US-20200046719-A1 | FUSED IMIDAZO-PIPERIDINE JAK INHIBITOR COMPOUND | JAK1, JAK2, JAK3 | TAAR1 2608/4885EGFR 464/4885UCHL1 4457/4885 |
| US-20140024634-A1 | INDAZOLES | JAK1, JAK3, JAK2 | TAAR1 3956/4885EGFR 1668/4885UCHL1 3356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.